FDC Limited announces a capital-allocation move
TL;DR
Based on the Letter of Offer and the latest financial statements, what is the projected impact of the buyback on FDC’s Return on Equity (ROE) and Earnings Per Share (EPS) post-extinguishment, and how does the total cash outflow compare to the company's free cash flow generation in the preceding fiscal year?
The buyback should be modestly accretive to ROE and clearly accretive to EPS, assuming the full ₹120 Cr buyback is completed and profit is unchanged. However, the exact post-extinguishment EPS cannot be quantified from the cited Letter of Offer extract because it does not state the buyback price or the number of shares ultimately extinguished.
ROE and EPS impact
- ROE: FY26 PAT was ₹281.42 Cr and total equity was ₹2,485.1 Cr, with reported ROE of 11.8% [1] [2] [3]. Deducting the ₹120 Cr buyback consideration from equity gives pro forma equity of approximately ₹2,365.1 Cr, assuming the entire amount is charged to equity [4].
- On an ending-equity basis, FY26 ROE would be approximately 11.9% (= ₹281.42 Cr / ₹2,365.1 Cr), versus the reported 11.8%—an indicative improvement of about 0.1 percentage point. The precise reported ROE impact may differ because the company’s ROE calculation may use average rather than ending equity and because the buyback occurs during FY27.
- EPS: FY26 diluted EPS was ₹17.29 [5]. If `N` is the pre-buyback share count and `B` is the number of shares extinguished, post-buyback EPS would be:
`Post-buyback EPS = ₹17.29 × N / (N − B)`
Thus, EPS rises by the inverse of the reduction in shares. The exact rupee EPS and percentage accretion require the Letter of Offer’s buyback price and the final number of shares accepted. The ₹120 Cr amount alone is insufficient to calculate them.
The latest Q2 FY27 financial data shows PAT of ₹49.06 Cr, diluted EPS of ₹3.01, ROE of 1.9% and total equity of ₹2,668.9 Cr [6] [7] [8] [9]. These are quarterly figures, so FY26 remains the cleaner full-year base for the above mechanical comparison.
Cash outflow versus free cash flow
Using FY26 revenue of ₹2,170.9 Cr [10], OCF-to-revenue of 9.2% [11] and capex-to-revenue of 8.6% [12]:
- Estimated OCF: approximately ₹199.7 Cr
- Estimated capex: approximately ₹186.7 Cr
- Derived FY26 free cash flow: approximately ₹13.0 Cr
Against the disclosed maximum buyback consideration of ₹120 Cr [4], the cash outflow is approximately 9.2 times FY26 free cash flow and exceeds that year’s derived FCF by roughly ₹107 Cr. Because the OCF and capex ratios are rounded, the FCF comparison is approximate; it also shows that the buyback is being funded from accumulated liquidity or balance-sheet cash rather than from a single year’s internally generated free cash flow.
How does the buyback size as a percentage of FDC’s net worth compare to the capital allocation strategies of mid-cap pharmaceutical peers who have executed buybacks in the last 24 months, and does this signal a shift in FDC's historical approach to cash management?
FDC’s proposed ₹120 Cr buyback equals approximately 4.8% of FY26 consolidated net worth, using total equity of ₹2,485.1 Cr as the net-worth proxy: ₹120 Cr ÷ ₹2,485.1 Cr = 4.83% [4] [2]. This is consistent with the company’s stated 4.87% of consolidated paid-up capital plus free reserves [13]. It is meaningful, but not a balance-sheet restructuring event.
FDC buyback scale
Notes: † Derived calculation; the regulatory denominator used by FDC is paid-up capital plus free reserves, not necessarily total equity.
Peer comparison
A like-for-like comparison with SPARC, Innova Captab, IOLCP, Orchid Pharma and Bliss GVS cannot currently be established: buyback execution, size and net-worth percentages for these companies over FY25–Q2 FY27 could not be confirmed.
SPARC
No comparable buyback amount or execution could be confirmed for FY25–Q2 FY27. Its disclosed capital-allocation framing remains focused on scientific investment, particularly oncology and immunology, with an emphasis on disciplined capital deployment [16]. This is strategically different from FDC’s cash-return action, but not a quantified peer buyback comparison.
Innova Captab
No comparable buyback amount or execution could be confirmed for FY25–Q2 FY27. Its Q2 FY27 consolidated net debt was ₹340.62 Cr [17], making its balance-sheet context materially different from FDC’s debt-free position.
IOL Chemicals and Pharmaceuticals
No comparable buyback amount or execution could be confirmed for FY25–Q2 FY27. The available management commentary points instead to internally funded growth investment: proposed projects were to be funded through internal accruals, with approximately 30% of the requirements already incurred [18]. IOL therefore provides evidence of a reinvestment-led capital-allocation approach, not a directly comparable buyback benchmark.
Orchid Pharma
No comparable buyback amount or execution could be confirmed for FY25–Q2 FY27. Orchid reported Q2 FY27 net debt of ₹497.04 Cr [19], again making a direct comparison with FDC’s cash-return capacity inappropriate without normalising for leverage and liquidity.
Bliss GVS Pharma
No comparable buyback amount or execution could be confirmed for FY25–Q2 FY27. Bliss had net cash of ₹36.81 Cr in Q2 FY27 [20], but no buyback amount or comparable capital-return programme could be confirmed.
Does this mark a change in FDC’s cash-management approach?
It signals an incremental change in capital-allocation mix, but not yet a proven structural shift. FDC was debt-free at FY26 and Q2 FY27, with cash and equivalents of ₹48.68 Cr and ₹36.21 Cr, respectively [21] [22] [23] [24]. At the same time, it continued to invest in capex, including ₹186.56 Cr in FY26 [15]. That pattern is consistent with a balance-sheet-conservative business that has historically retained liquidity while funding operations and investment.
The buyback changes the emphasis by making shareholder distribution a more explicit use of surplus capital. However, the maximum ₹120 Cr consideration is substantially larger than FDC’s Q2 FY27 cash balance, so it should not be interpreted as merely distributing idle cash; execution will depend on operating cash generation and the broader liquidity position.
A complete prior history of FDC buybacks, dividends and cash-retention policy could not be confirmed. The defensible conclusion is therefore: FDC is adding a material shareholder-return component to an historically debt-free, investment-funded model, but one buyback does not establish a permanent departure from its prior cash-management philosophy.
| Metric | FDC | Interpretation |
|---|---|---|
| Maximum buyback consideration | ₹120 Cr [4] | Cash return through tender offer |
| FY26 consolidated total equity | ₹2,485.1 Cr [2] | Net-worth proxy |
| Buyback as % of net worth | 4.8%† | Derived from the above figures |
| Shares proposed | 24 lakh, or 1.47% of paid-up capital [14] | Limited share-count reduction |
| Buyback as % of FY26 capex | 64.3%† | Derived from ₹120 Cr buyback and ₹186.56 Cr FY26 capex [15] |
Per the Corrigendum and Offer Opening Advertisement, what specific adjustments were made to the buyback timeline or terms, and how do these changes impact the total number of shares proposed to be bought back relative to the maximum buyback size?
The corrigendum/offer-opening advertisement did not expand the buyback. It confirmed the operative timetable as an offer opening on 19 November 2026 and closing on 26 November 2026; the record date remained 13 November 2026. The Letter of Offer also specifies 3 December 2026 as the subsequent settlement/payment milestone. [25] [26]
The core terms remained:
- Buyback price: ₹500 per equity share.
- Maximum consideration: ₹120 Cr, excluding transaction costs.
- Maximum shares: up to 24,00,000 equity shares. [25]
The relevant term clarification is that the company could increase the buyback price and correspondingly reduce the number of shares, provided the aggregate buyback size remained unchanged. [27] However, the final offer terms continued to state ₹500 per share and up to 24 lakh shares; therefore, there is no evidence of an actual change in the maximum quantity.
Impact: 24,00,000 shares × ₹500 = ₹120 Cr. Thus, the proposed quantity remains the maximum 24 lakh shares, not an amount in addition to the ₹120 Cr cap. If the price had been increased, the number of shares would have fallen to keep the maximum buyback consideration at ₹120 Cr; no such reduction is reflected in the published offer terms. [25]
Sources
- [1]TTM PAT
- [2]Total Equity
- [3]TTM ROE
- [4]FDC Limited Buyback Offer Opening Advertisement and Corrigendum — 2026-11-18T11:54:36.403000, p.4
- [5]TTM Diluted EPS
- [6]PAT
- [7]Diluted EPS
- [8]ROE
- [9]Total Equity
- [10]TTM Revenue INR
- [11]TTM OCF to Revenue
- [12]TTM Capex to Revenue
- [13]FDC_Ltd_291026 — D162Horukp7Uyq, 2026-10-29T00:00:00
- [14]FDC Ltd — Please find enclosed a copy of the Letter of Offer dated Nov | BazaarWatch — Bazaarwatch, 2026-11-16T00:00:00
- [15]TTM Capex
- [16]Innovations Inspired by Life - sparc.life — Sparc, 2026-07-16T00:00:00
- [17]Net Debt
- [18]17 September 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze — Iolcp, 2026-09-17T00:00:00
- [19]Net Debt
- [20]Net Debt
- [21]Total Debt
- [22]Total Debt
- [23]Cash and Equivalents
- [24]Cash and Equivalents
- [25]FDC_Ltd_161126 — Multibagg, 2026-11-16T00:00:00
- [26]NOTICE — BSE India, 2026-11-02T00:00:00
- [27]October 29, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G. — Nsearchives, 2026-10-29T00:00:00
Keep digging